DrDiamond
Merger has always been a possibility
« Thread started on: Today at 11:08am »

--------------------------------------------------------------------------------
We have always mentioned that a merger was a possibility and a probability for CMKX for many reasons. Although some recent poster is trying to make a claim to fame of coming up with the idea of a merger for CMKX you would have to go back a couple of years to get the first mention of this for CMKX. And more recently over the last few months, others of us have mentioned the real possibility of a merger, but held back due to the sensitivity of the information to the possible plan. So I will attempt to be as generalized as possible in this post.

Some things to consider are that Merger news tends to make investors crazy. Sometimes the acquisition efforts pan out, sometimes they don't. Sometimes the acquirer's stock fades on the news while the target company advances; sometimes they both fall. The factors in a merger that can cause price movement are endless. Usually investors first want to know if the acquiring company, whether CMKX or another is going to dilute its stock by issuing a ton of new shares to make the purchase. If the deal is for stock, then the acquiring company's shares will typically fall on the news. If the deal is for cash, then investors might fear that the acquirer is overpaying or facing a burdensome debt load another which would be another reason some might decide to punish its stock and drive the PPS down by selling.

Shares in the target company, such as CIM or UCAD would obviously rise on merger news when the bid comes in at a substantial premium to their current price. Occasionally the bid is not much of a premium, indicating that the acquirer thinks shareholders will be willing to sell out at almost any reasonable price. In those cases, the shares will often fall sharply in value. In any event, despite grand pronouncements by companies, Investors are usually dubious of the merits of acquisitions: The acquirer is often considered guilty of over stepping its abilities until proven innocent. The announcement of a merger should be neither a reason to buy or sell a stock. Find the acquiring company's press release and SEC forms, and thoroughly read them to determine whether it will enhance the value of your shares or not.

Often mergers take months to consummate, so you won't have to act right away. Study all available materials closely before deciding whether to stay in your shares, sell, or buy more. Mergers are not always received well by both companies but there is another option that takes the sting out of the merger equation.

Since mergers have been brought up again we might as well take a look at a very real possibility that lies before us. This is an option that has not been taken into consideration by many when looking to a merger and that is the possibility of a form of what I would call a “strategic merger”. The strategic merger I am referring to has been given a term called a “reverse merger”. This is not a very familiar term to the average investors but it is a very useful tool if CMKX chooses to utilize it. CMKX could use this and may very well have a plan set up for the use of this technique. UCAD may not fit the build perfectly but could be used or some other company we relate too, such as CIM, could very well be a prime candidate for a "reverse merger" with the exception that CIM is non-reporting at this time. A situation that could quickly be remedied or could be IPOed at an upcoming date.

A reverse merger is a process or method by which a company such as CMKX can use to go public or reach an exchange. Let’s take a brief look at what we can find in a reverse merger. In a perfectly situated reverse merger, a private company (non-reporting) merges with a public listed company with no assets or liabilities similar to CIM. This type of a public company is also called a "shell" corporation. The reason that this publicly traded corporation is called a "shell" since all that exists of the original company is its corporate shell structure.

By CMKX merging into such an entity, the company could become available on an exchange very quickly with very little hangover possibility. With all assets in tact CMKX could emerge from a non-reporting status in the Pink Sheets to a fully reporting status on the OTCBB, AMEX, etc…

In this scenario CMKX would merge into a fully reporting company and obtains the majority of its stock (usually 90%) and would also normally change the name of the shell corporation (often to its own name) and will appoint and elect its management and Board of Directors. The new fully reporting corporation has a base of shareholders sufficient to meet the 300 shareholder requirement for admission to quotation on the AMEX or the NASDAQ SmallCap Market.

The advantages of CMKX becoming fully reporting and moving to exchange trading status is notable including the possibility of commanding a higher price for a later offering of the company's securities in an IPO. Going fully reporting through a reverse merger allows a company to achieve these desired results typically at a lesser cost and with less stock dilution than through an initial public offering (IPO). While the process of going newly public and raising capital is combined in an IPO, in a reverse merger (also know as a "blind pool" merger) these two functions are unbundled; a company can accomplish these goals without raising additional capital. Through this unbundling process, the process of going newly public is simplified greatly.

If CMKX chooses to go this route then they obtain the benefits of the newly public trading of its securities on its own exchange, namely:
• Increased liquidity of the ownership shares of the company
• Higher share price and thus higher company valuation
• Greater access to the capital markets through the possibilities of a future stock offering
• The ability of the company to make more effective acquisitions of other companies using the company's stock minimizing dilution on a purchase
• The ability to use stock incentive plans to attract and retain key employees
The benefits of going newly public through a reverse merger, as opposed to an IPO, are the following:
• The costs are significantly less than the costs required for an initial public offering
• The time required is considerably less than for an IPO
• Additional risk is involved in an IPO in that the IPO may be withdrawn due to an unstable market condition even after most of the up-front costs have been expended
• IPOs generally require greater attention from top management
• While an IPO requires a relatively long and stable earning history, the lack of an earning history does not normally keep a privately-held or non-reporting company from completing a reverse merger
• The company does not require an underwriter
• There is less dilution of ownership control
• You will receive a higher valuation for your company
Requirements prior to entering into a reverse merger are the following:
• A private or non-reporting company will require approval of the majority of its stockholders for a merger with a fully reporting public corporation even if it is a shell company
Once a company is taken newly public through a reverse merger the financial markets hold the following future prospects in the capital markets for the newly public corporation:
• The market value of a public company is often substantially higher than a private or non-reporting company with the same structure in the same industry
• Capital is easier to raise for because the stock has an established and proven market value and can be readily traded
• The public trading price of the public company's securities serves as a benchmark for the offer price of a subsequent public or private securities offering
• Form S-8 stock can be issued for officers, directors and consultants
• If the stock dividend distribution included warrants, the new company can receive proceeds from the exercise of those warrants if the trading price of its common stock exceeds the exercise (strike) price of warrants.
(source for reverse merger information can be seen at http://www.ipo-merge.com/reverse.html)

Helping us stay informed.

Just opinions and speculations and I ask that you treat them as such.

holyguy7
MEGA-MERGER PREDICTIONS
« Thread started on: Today at 03:48:10 »

--------------------------------------------------------------------------------
MEGA-MERGER PRIDICTIONS
By Holguy7

Well, the mega-merger seems to all be coming together. I want to give you a few predictions that will happen in the near future as press releases come out.

1. We will dish out the 500,000 to purchase the remaining 24% of Juina. (I am almost positive on this one.)
2. We will purchase though cash or stock swap the remaining 20% of Yellow River.
3. We will purchase though cash or stock swap the remaining 20% of COD Mine.

According to the last Press Release, we have an 'option' to purchase the additional 24% of Juine for $500,000. The thing that seems odd about this is that we just got done purchasing 25% for $500,000 and will pay the SAME PRICE for 24% more. This, to me, makes it obvious that it was all prearranged that way.

Now, follow me here. When we get done purchasing Juina, UCAD and CMKX will together own quite a few companies. Let me break this down:

Juina- 51% owned by UCAD, 49% owned by CMKX after option of purchase is placed.
Nevada Magnetics- 100% owned by UCAD
Yellow River- 80% owned by UCAD
COD Mine- 80% owned by UCAD
Nevada Minerals- 40% owned by UCAD, 60% owned by CMKX.
CIM- CMKX has 10% royalties on minerals.

It appears pretty obvious that there is going to be a merger between CMKX and UCAD. This will mean:

Juina, Nevada Magnetics, Nevada Minerals, UCAD and CMKX will become ONE MEGA-MINING CORPORATION.

You can possibly add in there Yellow River and COD Mine as well if CMKX or UCAD gets 20% ownership of those claims.

Why is CMKX the one that spearheaded this MEGA-MERGER? There are a few reasons that come to mind.

1. CMKX has apparently GOOD financial backing to afford to do this.
2. CMKX has the majority of the land claims. At 1.5 million acres, they have the vast majority of claims in the region.
3. CMKX paid for the expensive arial surveys. These were not cheap and were definitely 7 figures to do. Millions of dollars to accomplish. Thus, they know exactly where the best places to pool resources to get maximum profits.
4. CMKX has hired one of the best corporate lawyers (D. Roger Glenn) in the country to do this.
5. CMKX has a genius via Urban Casavant as CEO.

These small companies are not stupid. Why limp along mining for years and years to come? Why not ride the gravy train by pooling resources and joining forces? United we stand, Divided we fall.

One more thing. Don't expect to get the share structure announced until after the MEGA-MERGER is accomplished. Why? Well, think about it. The share structure will then be announced as ONE UNIFIED COMPANY.

Can you tell me please?

More Diamonds From Saskatchewan Sampling

By Ketan Tanna Posted: 7/30/2004 1:37 AM

(Rapaport...July 30,2004) Shore Gold Inc. has recovered its third set of diamonds from the company's Star Diamond project in Saskatchewan. This includes the “the largest diamond yet discovered in Saskatchewan,” according to a company press release issued on July 29.

Topic: ECPN could be the next target of CMKX... (Read 1025 times)
driller
Diamondologist
member is offline
Gender:
Posts: 459
ECPN could be the next target of CMKX...
« Thread started on: Today at 1:43pm »

--------------------------------------------------------------------------------
UCAD struck a deal with them on May 14th.

The Chinese are buying their iron ore originally set a tonnage of 1,800,000 tons. They just put out a PR on the 28th that the Chinese upped their tonnage contract to 3 million tons out of the Capitan,NM site. That site has another estimated 22 million tons of iron ore in reserve after that deal.

ECPN also owns the COD complex of mines near Kingman,AZ... that are going to be an instant cash cow from the tailings ponds they will have GOLD AND SILVER in the next 30-60 days that was back on may 13th. That puts them into production right about now.

They also have copper,lead and zinc.

UCAD supplied a 3 person crew, operating capital for 90 days,fuel, equipment and the the maintenance. ECPN manages the operations relating to the ponds.

In exchange UCAD gets 50% of the revenue from the tailing ponds of gold and silver that should be coming anyday now since they should be in production already.

Now get this... UCAD acquired 80% ownership of the mining claims of the COD mines in AZ in exchange of 720,000 shares.

Now since this PR was dated May 13th and UCAD's contract runs out after 90 days (which is August 13th just 7 days before the dividends will be distributed to CMKX shareholders) with the tailings pond for gold and silver which is already in production more than likely by now... look for CMKX to be cutting a deal with them too.

Remember what I was telling all of you months ago that they would be exchanging equity into other projects and companies that are operating bringing in immediate cash flows both foreign and domestic.

Have anyone of you found out what the spot price of a ton of iron ore is? Have none of you noticed those PR's of tonnage of ECPN's Chinese iron ore deals have no valuations of the iron ore on them? The iron ore spot market is at least $40-45 a ton.. that's right! So that deal with the Chinese is worth are you ready for this .....
$150,000,000 dollars and there is another 22 million estimated tons left of iron ore in Capitan,NM... that means the mine could be worth up to $990,000,000!

That doesn't includes the testing that is showing up that includes traces of palladium and others.

Now get this UCAD also struck a deal to be a consultant to UPCN for 2 years with an option to buy 1,000,000 shares at .43 cents and get this.. to study and identify merger ventures acquisitons,jv's and strategic alliances.

Can you say cash cow for gold and silver which is already probably bringing in revenues as we speak, mega iron ore deals and other in demand minerals at 2 different sites in NM and AZ worth over a billion dollars right off the top for starters.

This has Urban written all over it.

Today is the last day you can buy shares before the 3-1 forward split takes place. They will be free trading and will not be restricted and should be in mine account by next week I was told. The AS will be increased from 50 Million to 100.. so the pps will dip maybe half of it's value.. but it will be temporary and should bounce right back up with all of the good news coming soon like minings tailing gold and silver being delivered, iron ore valuation in the hundreds of millions of dollars, in my opinion CMKX becoming a partner this will all come out after the 3-1 split in my opinion and with that news it will go back up.

The end result is that i think Urban will have a cash cow to join his ranks of growing companies and this one will bring in huge valuations with instant cash flow and sustained profits for years to come.

Driller http://c m k x . p r o b o a r d s 3 5.com/index.cgi?board=general&action=display&num=1091213010

Posted by: zeninvestor32
In reply to: None Date:7/30/2004 9:50:51 PM
Post #of 66960

WHAT TO EXPECT??

2 news releases last week.
3 news releases this week.
How many news releases next week?

I believe this will continue to accelerate as the end of the month approaches.

Anyone notice Shore Gold's and Kensington's performances over the past 2 days? The FALC region is hot and seems to be getting hotter.

Roger formally stepped on board just under 2 months ago. IMO we are just beginning to see the tip of his master plan. I reiterate that empire building is not a hasty process. The fact that we are already seeing the plan unfold is impressive. No we didn't get Xmas in July but I think things are progressing towards a blistering hot August. When you increase the heat one degree at a time, eventually water boils. I don't know what event will tip us past the boiling point, but I still firmly believe it will happen before September 1. My guess is that JEFF and his buddies are betting against that. Very bad bet IMO.

Z

As always, these are my personal opinions.

Q: What did the ruby say to the diamond?
A: You're so clear you make me blush!

Q: A man asked his girlfriend to marry him by getting down on his knees and offering her one beautiful diamond earring. She accepted happily but asked why her engagement gift was only a single earring.
A: He replied, "I'm on a lobe budget."

Q: What do you call it when a dog eats your wedding ring?
A: A Diamond in the "Ruff."

This weekend, lets speculate on why
« Thread started on: Jul 30th, 2004, 8:14pm »

quote:

---

Originally posted by noahltl:
newbe, can't forsee anything that would allow that to happen. Maybe if you were an MM, but that would be the only way IMO.

---

PinkSheets lists the BEST BID @ .0003 for 1000000shares what does that that mean then.
They know all about the situation too?

By: pedro20040
30 Jul 2004, 10:15 PM EDT
Msg. 55745 of 55864
Jump to msg. #
Information on O/S that may be of interest.

I was rereading the SEC purchase contract filed by UCAD.

A lot of people questioned about UC holding more than 50% of the outstanding shares of CMKM.

I believe I may have proof that this is true.

-------------------------------------------------------------

I believe we are all aware that corporate decisions must be approved by:
1. The Board of Directors , and
2. A majority shareholder approval (51%).

In order for CMKM to approve the sales of assets to UCAD, both items above must have been approved at some unknown meeting.

I was never mailed any voting ballots nor have I signed a proxy allowing another individual to vote on my behalf.

So let’s stick with item 2 above “A majority shareholder approval (51%).”

Under Nevada Corporate Law any decisions to buy and/or sell assets of the corporation must be approved by a majority shareholder vote.

NRS 78A.070 Shareholders’ agreements: Authority to enter; effect; amendment.
1. All shareholders of a close corporation who are entitled to vote may agree in writing to regulate the exercise of the corporate powers and the management of the business and affairs of the corporation or the relationship among the shareholders of the corporation.
http://www.leg.state.nv.us/NRS/NRS-078A.html#NRS078ASec080

--------------------------------------------------------------

I was reviewing the UCAD purchase agreement and discovered something very interesting. (Section 5..)

5.1 Organization of Seller; Authorization. Seller is a
corporation duly organized, validly existing and in good standing
under the laws of Nevada with full corporate power and authority to
execute and deliver this Agreement as it pertains to any
representations or untertakings of Seller. The execution,
delivery and performance of this Agreement has been duly
authorized by all necessary corporate actions of Seller and this
Agreement constitutes a valid and binding obligation of Seller,
enforceable against it in accordance with its terms.
http://www.sec.gov/Archives/edgar/data/1104194/000123224704000032/enio12.txt

-----------------------------------------------------------------

At some time there was a meeting held about the sale of assets to UCAD.

At this meeting CMKM Board of Directors voted and approved the sell of assets to UCAD.

At this meeting a majority interest (more than 51%) of CMKM Shareholders voted and approved the sell of assets to UCAD.

------------------------------------------------------------------

The same scenario is used for the purchase of “25% of Juina Mining.”

At some time there was a meeting held about the purchase assets in Juina Mining.

At this meeting CMKM Board of Directors voted and approved the purchase of assets in Juina Mining.

At this meeting a majority interest (more than 51%) of CMKM Shareholders voted and approved the purchase of assets in Juina Mining.

/
/
/
/
/

EDTA chelation has frequently been compared to a "Roto-Rooter" in the cardiovascular system, because it removes plaque and returns the arterial system to a smooth, healthy, pre-atherosclerotic state. A better metaphor might be "Liquid-Plumr," because, where Roto-Rooter violently scrapes deposits off the interior surfaces of your plumbing with a rapidly rotating blade, Liquid-Plumr simply dissolves them away.

Roto-Rooter is a far better metaphor for conventional medical treatments for heart disease, all of which are closely tied to the concept of the cardiovascular system as plumbing. When a pipe/artery gets clogged, simply ream it out or flatten the deposits (angioplasty). If that doesn't work, just cut away the bad section(s) and replace it (them) with a new piece of pipe (coronary artery bypass graft, or CABG). It's the same basic strategy older cities use for replacing their century-old water mains. And we know how successful that is!

It is commonplace for physicians who regularly prescribe EDTA chelation to encounter heart disease patients who have failed all the standard treatments but who make remarkable - even unbelievable - recoveries once given EDTA. While the jury is still out on EDTA Oral Chelation Therapy for improved circulation, better cardiovascular funtion, and general overall circulatory system and heart health, the signs all point to some positive results for EDTA use.


All Available Sizes of this Item
Size Item No. Retail Discount Our Price
120 Capsules 9761 15.90 60% 6.35
250 Capsules 9762 30.65 60% 12.25

EDTA Chelation
The Real "Miracle" Therapy for Vascular Disease

The story of EDTA chelation therapy is as much political as it is medical. Consider these facts:

EDTA chelation may be one of the most effective, least expensive, and safest treatments for heart disease ever developed, yet it is practiced by perhaps only 2,000 physicians in the United States.
EDTA chelation is not typically covered by medical insurance, even though insurance companies would save billions of dollars each year if they did.
Although they save far more lives than conventional treatments for heart disease and other chronic degenerative diseases at a fraction of the cost, physicians who practice and promote EDTA chelation for these uses have been harassed, vilified, smeared, and, in some cases, driven from their profession by powerful medical societies and government agencies that practice and promote conventional medical treatments.
What Is EDTA Chelation?
EDTA chelation is a therapy by which repeated administrations of a weak synthetic amino acid (EDTA, ethylenediamine tetra-acetic acid) gradually reduce atherosclerotic plaque and other mineral deposits throughout the cardiovascular system by literally dissolving them away.

EDTA chelation has frequently been compared to a "Roto-Rooter" in the cardiovascular system, because it removes plaque and returns the arterial system to a smooth, healthy, pre-atherosclerotic state. A better metaphor might be "Liquid-Plumr," because, where Roto-Rooter violently scrapes deposits off the interior surfaces of your plumbing with a rapidly rotating blade, Liquid-Plumr simply dissolves them away.

Roto-Rooter is a far better metaphor for conventional medical treatments for heart disease, all of which are closely tied to the concept of the cardiovascular system as plumbing. When a pipe/artery gets clogged, simply ream it out or flatten the deposits (angioplasty). If that doesn't work, just cut away the bad section(s) and replace it (them) with a new piece of pipe (coronary artery bypass graft, or CABG). It's the same basic strategy older cities use for replacing their century-old water mains. And we know how successful that is!

"Because EDTA is so effective at removing unwanted minerals and metals from the blood, it has been the standard 'FDA-approved' treatment for lead, mercury, aluminum and cadmium poisoning for more than 50 years."

CABG, known affectionately in the medical profession as "cabbage," is the most frequently performed surgery in the United States. At up to $50,000 per procedure, that indeed amounts to a lot of "cabbage," not only for cardiac surgeons but also for hospitals. As we shall see, these figures provide a powerful incentive for physicians to reject an effective, but inexpensive and unpatentable treatment like EDTA chelation.

It is commonplace for physicians who regularly prescribe EDTA chelation to encounter heart disease patients who have failed all the standard treatments but who make remarkable - even unbelievable - recoveries once given EDTA. Other patients, on waiting lists for CABG surgery, found they did not need the surgery following a series of EDTA chelation treatments.

EDTA exerts its beneficial effects on the body because this molecule is extremely proficient at chemically bonding with mineral and metal ions. This bonding process, known as chelation, is a natural and essential physiologic process that goes on constantly in the body. EDTA's chelating abilities make it ideal for many tasks:

Because EDTA is so effective at removing unwanted minerals and metals from the blood, it has been the standard "FDA-approved" treatment for lead, mercury, aluminum and cadmium poisoning for more than 50 years. EDTA normalizes the distribution of most metallic elements in the body.
Because it is so safe and effective, EDTA is also used widely as a stabilizer for packaged food. Minute amounts of EDTA (33-800 PPM) added to food help to preserve flavor and color and to retard spoilage and rancidity. (Read your food labels.)
Because EDTA inhibits blood clotting so well, it is routinely added to blood samples that are drawn for testing purposes.*
EDTA improves calcium and cholesterol metabolism by eliminating metallic catalysts that can damage cell membranes by producing oxygen free radicals.
Thanks to these and probably other effects of EDTA, it has been reported to have a wide variety of benefits.

*If you followed the O.J. Simpson trial, you probably know that EDTA was featured prominently. The defense contended that EDTA, supposedly found in certain of "The Juice's" blood drops at the murder scene, indicated that that blood had spent some time in a collection tube before being "planted" by the LAPD. If there was EDTA in Simpson's blood, though, it may well have come from the meal he ate on the plane ride from Chicago to LA.

EDTA Chelation vs. Conventional Therapy for Vascular Disease
Researchers first started to notice EDTA in the days during and after World War II when men who worked in battery factories or painted ships with lead-based paint began coming down with lead poisoning from their high exposure in these jobs. EDTA was found to be extremely effective for removing the lead from the men's bodies, but what really made people sit up and take notice was an apparent reduction in symptoms of heart disease in many of these men.

The first systematic study of EDTA in people with atherosclerosis was published in 1956.1 When the researchers gave 20 patients with confirmed heart disease a series of 30 I.V. EDTA treatments, 19 of the patients experienced improvement, as measured by an increase in physical activity. Another study 4 years later in a similar population found that 3 months of EDTA infusions resulted in decreases in the severity and frequency of anginal episodes, reduced use of nitroglycerin (a common anti-angina drug), increased work capacity and improved ECG (electrocardiogram) findings.2

It soon became clear from these and later studies that EDTA treatments result in progressive and widespread improvement and stabilization of cardiovascular function. This is in contrast to standard treatments, such as angioplasty or CABG, which instantaneously restore normal function in the few treated arteries, but leave the rest of the body completely untreated (there's every reason to believe that if arteries are clogged in the heart, they're also clogged in other vital organs, like the kidneys and brain). High-tech treatments for heart disease, such as angioplasty and CABG, long hailed as medical breakthroughs, are in fact, oversold, overpriced, and ineffective, especially when compared with EDTA chelation. The truth of this assertion has been demonstrated on numerous occasions over the last 2 decades:

The average mortality for CABG surgery is 4% to 10%.3,4 In fact, CABG has no overall effect on improving survival. According to one study published in the New England Journal of Medicine, "As compared with medical therapy, coronary artery bypass surgery appears neither to prolong life nor to prevent myocardial infarction in patients who have mild angina or who are asymptomatic after infarction in the five-year period after coronary angiography."5 By contrast, mortality rates for EDTA chelation, when carried out according to accepted protocols, approaches 0%.6
Grafted coronary arteries are more than 10 times as likely to close up again within 3 years compared with coronary arteries that are not replaced with a graft.7 Improved blood flow following EDTA chelation therapy is permanent as long as regular EDTA therapy (either oral or I.V.) is maintained.
Significant cerebral dysfunction, especially in older patients, is commonly seen following CABG.8 Because EDTA chelation restores blood flow to the brain, it often results in improved cognition and memory.9
Atherosclerosis is typically a body-wide disease. If your coronary arteries are occluded, it's a safe bet that arteries in your brain, kidneys, lungs, and other vital organs are also occluded. Angioplasty or CABG can clean out only a few arteries supplying the heart. Another surgical procedure, endarterectomy, is commonly used to clear out the carotid arteries that supply the brain. When patients who have undergone carotid endarterectomy are treated with EDTA afterwards, the degree of subsequent restenosis (re-occlusion) drops by 10%.10
Despite the danger and costs associated with these procedures, they are often only temporary fixes. Restenosis of treated coronary arteries occurs within 6 months in as many as one in three cases.11 By contrast, EDTA chelation permanently removes blood vessel obstructions throughout the body without dangerous and expensive surgery. How well does EDTA chelation work? Virtually every study that has looked at the efficacy of EDTA chelation in vascular disease has demonstrated significant improvements. Here is a brief sampling of a few of the major results:
A 1993 meta-analysis of 19 studies of 22,765 patients receiving EDTA chelation therapy for vascular disease found measurable improvement in 87%.12
In a study of 2,870 patients with various degrees of degenerative diseases, especially vascular disease, almost 90% of the patients showed excellent improvement, as measured by walking distance, ECG, and Doppler changes.13
A small, blinded, crossover study of patients with peripheral vascular disease found significant improvements in walking distance and ankle/brachial blood flow.14
In 30 patients with carotid artery stenosis, there was a 30% improvement in blood flow after EDTA treatment.15
Using retinal photographs in patients with macular degeneration, one researcher demonstrated significant improvement following EDTA treatment.16
EDTA chelation treatment was evaluated in patients with carotid and coronary disease using technetium 99 isotope techniques. Significant improvement in arterial blood flow and ejection fraction (a measure of heart pumping ability) was reported.17,18
When 65 patients on the waiting list for CABG surgery for a mean of 6 months were treated with EDTA chelation therapy, the symptoms in 89% (58) improved so much they were able to cancel their surgery. In the same study, of 27 patients recommended for limb amputation due to poor peripheral circulation, EDTA chelation resulted in saving 24 limbs.19
Negative Results?
Of course there have been a few studies that did not (at first) seem to support the efficacy of EDTA chelation therapy. The most prominent apparently well-controlled studies have been two Danish trials 20,21 and a New Zealand trial,22 all of which reported no apparent benefits. A close analysis of these studies, however, revealed problems with both the controls and the interpretation of the data.

"Because EDTA chelation restores blood flow to the brain, it often results in improved cognition and memory."

As noted by Chappell and Janson,6 the standard EDTA chelation treatment protocol was not followed in these trials. They all included primarily smokers (notoriously poor responders) with severe vascular disease who received only 20 I.V. treatments. With such patients, 30 to 40 treatments are normally required before a significant effect is typically seen. Although the New Zealand trial was supposedly placebo-controlled, the "placebo" used actually had chelating properties of its own. Thus, the fact that the differences from "placebo" were small is meaningless.

When the raw data from the New Zealand study were examined, it was found that 26% of the EDTA-treated patients compared with only 12% of the "placebo" controls achieved an improvement of greater than 100% in walking distance; among nonsmokers or smokers who had quit, 66% of the EDTA-treated group increased their walking distance an average of 86% compared with 45% of the controls, who improved by just 56%. Reduced blood flow, as measured by the ankle/brachial index, was found in 6% of the EDTA-treated patients and 35% of the controls. Although the authors of these studies reached negative conclusions, in fact, their data actually supported the use of EDTA chelation.

How Safe Is EDTA Chelation?
EDTA, is a safe, nontoxic substance. The LD50 (so called when the dose will kill 50% of experimental animals) for EDTA is 2000 mg/kg body weight, which makes it about 3.5 times less toxic than aspirin. Although the FDA refuses to approve it for treating vascular disease, EDTA chelation has been the approved treatment for lead or other heavy metal poisoning for 50 years. When administered according to the treatment protocol developed by the American College for Advancement in Medicine (ACAM), I.V. chelation is more than 300 times safer than CABG surgery. Most side effects of treatment involve minor discomfort (eg, nausea, dizziness, headache) that resolves quickly.

The greatest risks occur when an infusion is given too rapidly or in too large a dose. These risks virtually vanish when EDTA is administered by a properly trained physician who follows the ACAM protocol. To the extent that oral EDTA is a completely noninvasive therapy, it is even safer than I.V. EDTA.

I.V. or Oral EDTA?
Most chelation therapy carried out today involves I.V. administration of EDTA, however, oral EDTA, which has a history at least as long as its I.V. cousin, is an option that is only now starting to be appreciated. Clinical experience suggests that oral chelation provides some, but not all, of the benefits of I.V. therapy. Overall, the difference in benefits is more one of degree and speed than of quality.

I.V. therapy has a direct and powerful effect on the body almost instantaneously. An I.V. session usually lasts about 3 to 4 hours, during which about 1500 mg to 3000 mg of EDTA (plus vitamin C and other nutrients) are administered. The number of treatments necessary (generally about 20-50 sessions) depends on the individual's condition. Candidates for I.V. chelation are people that have been diagnosed with serious atherosclerosis, heavy metal poisoning, or symptoms of vascular occlusion or significant calcification of tissues. Only about 3% to 8% of an oral dose of EDTA is absorbed, compared with 100% of an I.V. dose. Therefore, the time and dosage required to achieve the same benefits with the oral form are quite different. What can be achieved in only a few hours with I.V. EDTA chelation may take several weeks or months with oral EDTA chelation. However, oral EDTA may be appropriate for people whose condition does not demand rapid action. For example, oral chelation can be used to:

avoid complications and diseases that result from heavy metals and calcification
prevent the formation of blood clots, thus reducing your chance of a heart attack or stroke
lower the level of blood cholesterol
help thin the blood
aid in reducing lipid peroxidation, a major cause of atherosclerosis
protect the body against certain carcinogens, pathogens and other toxins that can reduce the quality of health
Oral EDTA is not meant to replace I.V. therapy for those people who have serious vascular disease. It is very useful, though, for people who have completed an I.V. course and want to stay on a maintenance program, for people who "for whatever reason" are unable or unwilling to undergo I.V. chelation, and for those whose I.V. treatments may have been interrupted.

The Politics of EDTA Chelation
Organizations like the American Heart Association and the American Medical Association, which condemn EDTA chelation as ineffective for treating vascular disease, often quote the Danish and New Zealand studies, mentioned earlier, to support their position.20-22 What they fail to mention is that the Danish studies were criticized by the Danish Committee for Investigation into Scientific Dishonesty because of improper randomization and double-blinding, as well as premature breaking of the blinding code, which amounted to a deliberate bias. When the results of the New Zealand study were examined by two independent statisticians, it was concluded that the trial actually supported the efficacy of EDTA.23

"Virtually every study that has looked at the efficacy of EDTA chelation in vascular disease has demonstrated significant improvements."

It is unlikely that any other issue in modern medicine has been more highly politicized than that of EDTA chelation therapy, and it is clear that most of the opposition to EDTA is due to the threat this therapy represents, not to patients' health but to the bank balances of orthodox physicians, pharmaceutical companies, and hospitals. Treating cardiovascular diseases is big business in the United States (and the rest of the Western world), bringing in tens of billions of dollars each year.

As Garry Gordon, MD, DO, the "Father of Chelation Therapy" has pointed out, "Every time a surgeon does a heart bypass, he takes home a luxury sports car." Each CABG procedure costs between $25,000 and $50,000; each angioplasty costs about $15,000; drugs for reducing cholesterol, lowering high blood pressure, and normalizing heart rhythm bring the pharmaceutical industry hundreds of millions of dollars each year. And these are just the most common examples. What happens when you add EDTA chelation therapy to this mix?

A course of I.V. EDTA chelation therapy costs between $2000 and $4000; oral EDTA is even less costly. To the degree that these therapies reduce the need for the more expensive conventional therapies - a large degree, indeed - they threaten to diminish the income of a significant portion of the medical establishment. Consider this one example: As noted earlier, in a study of 65 patients who were treated with I.V. EDTA while they were waiting for CABG surgery, 58 (89%) no longer required the procedure.19 At $50,000 per procedure not done, that means that surgeons and hospitals gave up nearly $3 million just for these few patients. Now remember, that CABG is the most common surgical procedure performed in the US (368,000 in 1989).24

Given these figures, it's not hard to understand why the medical profession is so in love with CABG and related procedures. As one physician noted, "It pays the bills." So enamored are they of these procedures that they perform them even when they are not necessary. In an article published in no less prestigious a publication than the Journal of the American Medical Association, the authors concluded that only 56% of the surgeries performed were for appropriate reasons, 30% for equivocal reasons, and 14% for inappropriate reasons. The percentage of appropriate surgeries varied from 37% in some hospitals to 78% in others.25 When you consider that even when it is "appropriate," CABG surgery is no better than conventional medical treatments for improving survival,5 you have to wonder whether the real "miracle" of heart surgery does not entail bringing people back from death's door, as much as turning a common chronic degenerative disease into a source of outrageous fortune. If you needed one example of why the cost of health care has gone into earth orbit, you need look no further than the conventional treatment of heart disease.

"If you needed one example of why the cost of health care has gone into earth orbit, you need look no further than the conventional treatment of heart disease."

Given these figures, it's also not very hard to understand why the medical profession has reacted so violently against physicians who practice chelation therapy, often attempting, in the words of that great seeker of medical truth (that's a joke folks), Dr. Victor Herbert, "to put them out of business." Because EDTA has long been approved for treating heavy metal poisoning, and because physicians are free to use any "approved" medication for any use they see fit, as long it does not endanger the patient, EDTA chelation therapy is perfectly legal. This has not stopped medical boards in a number of states from bringing charges against physicians who prescribe EDTA chelation for vascular disease, smearing them as "quacks," and attempting to restrict the use of this therapy. Fortunately, most of these attempts have failed.23

You can be certain that if EDTA had a large pharmaceutical company advocating its use, these problems wou quickly evaporate. But since the patent for EDTA ran out nearly 30 years ago, there are no huge profits to be made from marketing it. With no pot of gold at the end of the EDTA rainbow, no one is going to put up the hundreds of millions of dollars required to do the randomized, double-blind, placebo-controlled clinical trials required to get the FDA to approve EDTA for vascular disease. And with few large, randomized, double-blind, placebo-controlled clinical trials to refer to, the conventional medical establishment feels justified in condemning EDTA therapy as "unproven." It's a familiar "Catch 22" that faces all natural or unpatentable therapies.

Conclusion
While most American physicians choose to remain blind to the benefits of EDTA, those who prescribe it are free to witness its life-enhancing benefits on a daily basis. One of those physicians is Dr. Garry Gordon, whose own life was saved by EDTA and who has been a leader in chelation therapy since the early 1960s. "I have taken on patients who were inoperable, who had already had every known form of bypass surgery, who had no more veins in their legs to strip out and put into their heart, and who were sent home to die, and I could get those people back to full functioning," says Dr. Gordon.

For an interview with Dr. Garry Gordon, see Exclusive Interview with Garry Gordon, M.D., D.O.: Oral Chelation for Improved Heart Function - Apr. 1997

POTENTIAL BENEFITS OF EDTA CHELATION
Prevents cholesterol deposits
Reduces blood cholesterol levels
Lowers high blood pressure
Avoids by-pass surgery
Avoids angioplasty
Reserves digitalis toxicity
Removes calcium from atherosclerotic plaques
Dissolves intra-arterial blood clots
Normalizes cardiac arrythmias
Has an anti-aging effect
Reduces excessive heart contractions
Increases intracellular potassium
Reduces heart irritability
Improves heart function
Removes mineral and drug deposits
Dissolves kidney stones
Reduces serum iron levels
Reduces heart valve calcification
Reduces varicose veins Heals calcified necrotic ulcers
Reduces intermittent claudication
Improves vision in diabetic retinopathy
Decreases macular degeneration
Dissolves small cataracts
Eliminates heavy metal toxicity
Makes arterial walls more flexible
Prevents osteoarthritis
Reduces rheumatoid arthritis symptoms
Lowers diabetics' insulin needs
Reduces Alzheimer-like symptoms
Reverses senility
Reduce stroke/heart attack after-effects
Prevents cancer
Improves memory
Reverses diabetic gangrene
Restores impaired vision
Detoxifies snake and spider venoms
Adapted from Walker M., Gordon G., Douglass W.C. The Chelation Answer

References
1. Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci. 1956;December:654-666.
2. Meltzer LE, Ural E, Kitchell JR. The treatment of coronary artery heart disease with disodium EDTA. In: Seven M, ed. Metal-Binding in Medicine. Philadelphia: JB Lippincott; 1960.
3. Edmunds LH, Stephenson LW, Edie RN, Ratcliffe MB. Open-heart surgery in octogenarians. N Engl J Med. 1988;319:131-136.
4. CASS Principal Investigators and the Associates. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery: Survival data. Circulation. 1983;68:939-950.
5. CASS Principal Investigators and the Associates. Myocardial infarction and mortality in the Coronary Artery Surgery Study randomized trial. N Engl J Med. 1984;310:750-758.
6. Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs. 1996;10:78-86.
7. Cashin WL, Sanmarco ME, Nessim SA, Blankenhorn DH. Accelerated progression of atherosclerosis in coronary vessels with minimal lesions that are bypassed. N Engl J Med. 1984;311:824-828.
8. Arom KV, Cohen DE, Strobl FT. Effect of intraoperative intervention on neurological outcome based on electroencephalographic monitoring during cardiopulmonary bypass. Ann Thorac Surg. 1988;48:476-483.
9. Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988;27:41-49.
10. Holliday HJ. Carotid restenosis: A case for EDTA chelation. J Adv Med. 1996;9.
11. Parisi AF, Folland ED, Hartigan PA. Comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326:10-16.
12. Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med. 1993;6:139-160.
13. Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988;27:41-49.
14. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc. 1990;82:173-174.
15. Rudolph CJ, McDonagh EW, Barber RK. A non-surgical approach to obstructive carotid stenosis using EDTA chelation. J Adv Med. 1991;4:157-166.
16. Rudolph CJ, Samuels RT, McDonagh EW. Visual field evidence of macular degeneration reversal using a combination of EDTA chelation and multiple vitamin and trace mineral therapy. J Adv Med. 1994;7:203-212.
17. Casdorph HR. EDTA chelation therapy, II: efficacy in brain disorders. J Holist Med. 1981;3:101-117.
18. Casdorph HR. EDTA chelation therapy: efficacy in arteriosclerotic heart disease. J Holist Med. 1981;3:53-59.
19. Hancke C, Flytie K. Benefits of EDTA chelation therapy on arteriosclerosis. J Adv Med. 1993;6:161-172.
20. Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg. 1991;162:122-125.
21. Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication - a double-blind, placebo-controlled study. J Intern Med. 1992;231:261-267.
22. van Rij AM, Solomon C, Packer SGK, Hopkins WG. Chelation therapy for intermittent claudication: a double-blind, randomized, controlled trial. Circulation. 1994;90:1194-1199.
23. Schachter MB. Overview, historical background and current status of EDTA chelation therapy for atherosclerosis. J Adv Med. 1996;9:159-177.
24. Gundy P. Cardiovascular diseases remain nation's leading cause of death. JAMA. 1992;267:335-336.
25. Winslow CM, Kosecoff JB, Chassin M, Kanouse DE, Brook RH. The appropriateness of performing coronary artery bypass surgery. JAMA. 1988;260:505-509.



back to top

Home | About | Contact | Terms | Cart | Resellers | Help

Customer Service Questions? Call (800) 543-3873

Trading Wizard -Great Posts-ECPN-Great Find -wish I had been around more yesterday to buy some before the split. Waaah! CMKX looks to be positioning itself to be a mining mega power. I think regardless of what our ultimate share structure is, we will have a present value of .10 a share minimum based on current share structure. UC has been quoted as saying this is worth .50-.61 a share and that was a while ago and not considering any naked short squeeze.

This is very exciting. I do think the posts about MM tricks as we count down these last weeks are right. I hope posters who own CMKX understand the potential by now and do not sell too cheaply. I think getting a free share position is worthwhile if you don't have to give up to many shares to do so. I have 45+ Million shares now and would probably sell 5 Million at .01 not all at once but try to swing trade some shares in the .005-.03 range if we get there preannouncement. It would be fun to be able to lock in some profit and have lots of free shares. This has not been allowed to run and getting free shares may not be possible if the price continues to be sat on till September 3. In that case I am keeping all my risk but the possibility of a major life altering return is pretty good. It is a high risk. But a calculated one that I feel comfortable taking and not because I am rolling in dough. I trust the DD I have done on this stock. Thanks to all who have contributed valuable info and well considered opinions both pro and con. There have been good posts made with both views. Not all of them obviously, but keeping us aware of the unsubstantiated portion of what is posted is correct. Unfortunately this is a stock where we are basing a lot of our opinions on how we read the integrity of the people. Difficult to gauge in a fully reporting company. Much more difficult here. But UC has been available to meet and interact with at the races, Melvin has been very available via phone and certainly many long time shareholders believe UC to be a man of integrity and vision. We are almost there. GLTA-DD-IMO and I have to say God Bless. If this does come to pass I will see this as a blessing from God, ultimately He is my source regardless of what He uses to bless with.

Noah -Great posts as ususal

I have seen a few posts mentioning a large fee for selling the dividend after a year. If you (we) aren't able to profitably sell it after the fee we could hold it indefinitely and never pay a fee. It will either grow to something worthwhile or tank so low it would eventually disappear. I am thinking it will be good. I suppose if someone has a low number of shares it might not be worth trading. I think some of the value of the dividends especially CIM is to force a cover of the Naked short position.

quote:

---

Originally posted by rickp:
Does anyone think that CMKX played the part in the 7.5 Million share buy to catch the MM's with their pants down in order to count naked shares? I mean if they did look at it this way, if they give out 7.5 Million shares to all stock holders then those holding naked shares would be calling and saying what happened to my part of the 7.5? CMKX could count the naked shares this way to prove that they were naked shorted right?? Does anyone have any thoughts on this ?? I am holding 4.3 Million on CMKX and am long till $1.00

---

**DIAGEM SHIPS DIAMONDS**...Juinas' JV partner...

From UCADs' 10QSB May 21st '04...

The Company believes that acquiring Juina Mining will provide it with revenuesbased upon Juina's existing joint venture with DIAGEM International ResourceCorporation, a Canadian corporation, in the Juina Mining Mineracao, Ltd., a firmthat owns 86% of the mining and mineral rights to approximately 1000 hectares(2,477 acres approximately) of potential diamond bearing land in the province ofJuina Mato Grosso, Brazil. The property is located 342 miles north of the cityof Cuiaba by air or 450 miles by road near the major urban center of MatoGrosso. The area is serviced by air and land transportation.

From Diagems' web site...notice this is the only Alluvial Diamond Mining Program they have in Brazil..
http://www DOT diagem DOT com/todo/alluvialindex DOT htm

NOW...this article i just came across...Notice it says "second batch"...and the date on this article is July 26th '04.

Diagem prepares to sell diamonds recovered from Alluvial Diamond project in Mato Gross State, Brazil

Diagem International Resource Corp. announces that it has successfully completed its second export of Diamonds this year. This second export of 3,990 carats brings the total on hand to 7,438 carats. The diamonds were recovered from the Company's on-going Alluvial Diamond Project in Mato Gross State Brazil.

The diamonds are now being cleaned and prepared for sale. A detailed evaluation of the various parcels will be conducted once the cleaning process has been completed. This will represent the Company's first eagerly awaited sale of diamonds from its current projects this year and is expected to take place after the summer holidays in Antwerp.

Jacky Lewy, a Principal of Natural Diamond Corporation, the Company's strategic marketing partner, commented on the higher than expected proportion of good quality diamonds, that clearly demonstrates the significant potential of the Juina Diamond Province. He was particularly impressed by a 25 carat diamond.

Natural Diamond Corporation is a pre-eminent rough and polished diamond marketing company based in Antwerp, Belgium. Mr. Lewy, also a director of Diagem, is a founder of Natural Diamond with over 30 years experience in the diamond industry including the marketing of rough and polished diamonds.

Thanks for the "MAAAJJOOORRR DEVELOPEMENT" [sic] post.

I googled "rim of fire investment" and got only one result from a high school alumni directory:

Robert W. CZESCHIN [modified: 1-1998] invalid email
Hong Kong, SAR

Editor of two investment publications: "Czeschin's Oil & Energy Investment Report" and "The Rim of Fire Investment Alert," which are now read by 32,000 paid subscribers in 83 countries. Also author of the book titled: "The Last Wave: Oil, War & Financial Upheaval in the Final Days of the 20th Century," Shot Tower Books, (7th edition 1995).
___ http://www.laduealum.com/class1970.html
___
Do you mean to say that in the newsletters you must have already received, there is no mention of their website? Is any of the above confirmed in the newsletters?

Star, thanks for the off-topic EDTA post. Man, we complain about not trusting PRs and CEOs, but what's really tragic is that when someone goes to the doctor with heart issues, they trust HIM when he says, "You need surgery immediately, or you may die," and never mentions alternative remedies. After all, how else can the doc get his new Beamer?